Silver Creek Pharmaceuticals, based in San Francisco, CA, is a clinical stage biotechnology company focused on developing first-in-class biologic therapies to repair damaged brain, heart, and kidney tissue after acute injuries. Their Smart Growth Factor platform technology enables the rapid development of targeted therapeutics with broad applicability across various indications.
The company's lead therapy, scp776, is a novel fusion protein that harnesses the cell survival function of insulin-like growth factor IGF-1 to target injured tissue and promote Apoptosis Escape. With a commitment to delivering life-saving medicines to patients, Silver Creek is actively developing scp776 for the treatment of stroke and exploring applications for additional CNS diseases.
Generated from the website